Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Sinnett
Neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide Chemotherapy Followed by Docetaxel in Refractory Patients With Locally Advanced Breast Cancer
Oncology Reports
Medicine
Cancer Research
Oncology
Related publications
Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)
Scientific Reports
Multidisciplinary
Epirubicin/Cyclophosphamide Followed by Docetaxel as Primary Systemic Therapy in Breast Cancer
Annals of Cancer Research and Therapy
Cancer Research
Oncology
Pharmacology
Pharmacogenetics of Toxicity of 5-Fluorouracil, Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients
Oncotarget
Oncology
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
Journal of Cellular Physiology
Clinical Biochemistry
Cell Biology
Physiology
Prolonged Neoadjuvant Chemotherapy With GM‐CSF in Locally Advanced Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
The Influence of Obesity on Results of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients
Polski Przeglad Chirurgiczny
Medicine
Surgery
Neoadjuvant Docetaxel, Cisplatin and Fluorouracil Followed by Concurrent Cisplatin Intensity Modulated Radiation Therapy in Treatment of Locally Advanced Nasopharyngeal Carcinoma
Research in Oncology
Erratum To: Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients With Locally Advanced Rectal Cancer
Clinical Pharmacokinetics
Pharmacology
Low Expression of Stathmin in Tumor Predicts High Response to Neoadjuvant Chemotherapy With Docetaxel-Containing Regimens in Locally Advanced Breast Cancer
Genetic Testing and Molecular Biomarkers
Medicine
Genetics
